1. Home
  2. OSIS vs CRSP Comparison

OSIS vs CRSP Comparison

Compare OSIS & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OSIS
  • CRSP
  • Stock Information
  • Founded
  • OSIS 1987
  • CRSP 2013
  • Country
  • OSIS United States
  • CRSP Switzerland
  • Employees
  • OSIS N/A
  • CRSP 393
  • Industry
  • OSIS Industrial Machinery/Components
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • OSIS Technology
  • CRSP Health Care
  • Exchange
  • OSIS Nasdaq
  • CRSP Nasdaq
  • Market Cap
  • OSIS 3.4B
  • CRSP 3.3B
  • IPO Year
  • OSIS 1997
  • CRSP 2016
  • Fundamental
  • Price
  • OSIS $223.53
  • CRSP $35.62
  • Analyst Decision
  • OSIS Strong Buy
  • CRSP Buy
  • Analyst Count
  • OSIS 6
  • CRSP 17
  • Target Price
  • OSIS $228.33
  • CRSP $74.53
  • AVG Volume (30 Days)
  • OSIS 207.8K
  • CRSP 2.0M
  • Earning Date
  • OSIS 05-01-2025
  • CRSP 05-06-2025
  • Dividend Yield
  • OSIS N/A
  • CRSP N/A
  • EPS Growth
  • OSIS 13.25
  • CRSP N/A
  • EPS
  • OSIS 8.23
  • CRSP N/A
  • Revenue
  • OSIS $1,689,088,000.00
  • CRSP $37,675,000.00
  • Revenue This Year
  • OSIS $12.56
  • CRSP $51.35
  • Revenue Next Year
  • OSIS $5.14
  • CRSP $282.16
  • P/E Ratio
  • OSIS $26.98
  • CRSP N/A
  • Revenue Growth
  • OSIS 14.93
  • CRSP N/A
  • 52 Week Low
  • OSIS $129.18
  • CRSP $30.04
  • 52 Week High
  • OSIS $227.34
  • CRSP $67.88
  • Technical
  • Relative Strength Index (RSI)
  • OSIS 68.22
  • CRSP 44.74
  • Support Level
  • OSIS $215.34
  • CRSP $33.03
  • Resistance Level
  • OSIS $226.01
  • CRSP $39.38
  • Average True Range (ATR)
  • OSIS 7.06
  • CRSP 1.81
  • MACD
  • OSIS 2.20
  • CRSP -0.19
  • Stochastic Oscillator
  • OSIS 90.20
  • CRSP 33.64

About OSIS OSI Systems Inc. (DE)

OSI Systems Inc is a designer and manufacturer of electronic systems and components for businesses in the homeland security, healthcare, defense, and aerospace markets. The firm is organized in three business segments: Security, which derives maximum revenue, provides security and inspection systems; Healthcare, which provides patient monitoring, diagnostic, cardiology, ventilation systems and defibrillators; and Optoelectronics and Manufacturing, which provides specialized electronic components and manufacturing services for the Security and Healthcare segments and external original equipment manufacturers. Majority of the firm's revenue is generated in the United States, and the rest from Mexico, Europe, the Middle East, and Africa, and the Asia Pacific regions.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: